Gilead Sciences news from FierceBiotech
NewsC&L: Una Ryan leaves Avant
Avant Immunotherapeutics today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Watson Pharmaceuticals announced that co-founder and Chairman Allen Chao has Read more...
C&L: Wells named Biovail CEO
Biovail has named William Wells, Loblaw Cos. Ltd.'s chief financial officer, as its new chief executive, replacing Douglas Squires, who will become Biovail's chairman. ARUP Laboratories co-founder Read more...
Gilead Sciences - Big Biotech's Stock Report
Company: Gilead Sciences Starting stock price: $32.16 Ending stock price: $46.01 Percent Change: 43.06% Scoop: Gilead's big achievement of '07 was the Read more...
Big Biotech's Stock Report
2007 was a big year for Big Biotech, and while some of the top companies shined, other industry leaders took a beating. Biotech five biggest players--Amgen (1), Genentech (2), Biogen Idec (3), Read more...
ALSO NOTED: Genta inks licensing deal on oncology program; Abbott, et al, target Tarceva gene test; Gilead submits marketing ap
> Genta has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo for the development and commercialization of tesetaxel(formerly known as DJ-927), a late Phase II oncology Read more...
ALSO NOTED: Sirtris, NCI collaborate on cancer models; Kylin expands in Indiana; and much more...
> Sirtris announced a collaboration with the National Cancer Institute to its enzyme activators in cancer models. Read more...
ALSO NOTED: Stalevo posts positive Parkinson's data; Genzyme applauded for aggressive strategy; Philogen pulls IPO; and much mo
> Novartis has told Orion Corp.--which put out a press release--that Stalevo has produced positive data in a late-stage Parkinson's trial. Read more...
Letairis - 2007 FDA approvals
Drug: Letairis (ambrisentan) Indication: Pulmonary arterial hypertension Company: Gilead Sciences Approval Date: June 15, 2007 Scoop: Letairis is a once-daily endothelin receptor antagonist (ERA). Read more...
Press Release: Phase III Study Evaluating Gilead’s Viread Meets Primary EndpointPress Release: Phase III Study Evaluating Gilead’s Viread Meets Primary Endpoint Read more...Gilead touts Phase III Hep B resultsGilead is reporting that a Phase III trial of its HIV drug Viread was more effective at reducing amounts of the hepatitis B virus than the company's other antiviral drug, Hepsera. At 48 weeks, 66.5 percent receiving Viread had a complete response compared to 12.2 percent in the Hepsera arm. "The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, … Read more... | Press ReleasesPRESS RELEASE: Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary DiseaseParion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease Companies Will Initially Focus Research Efforts in Cystic Fibrosis DURHAM, N.C. and FOSTER CITY, Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends